Guidance Capital’s NeoGenomics NEO Stock Holding History

Guidance Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,869	Closed	-$725K	–	261
2025 Q4	$725K	Sell	55,869 -1,870	-3%	-$20.2K	0.18%	128
2025 Q3	$616K	Buy	57,739 +5,797	+11%	+$40.6K	0.16%	136
2025 Q2	$268K	Buy	51,942 +11,032	+27%	+$89K	0.08%	183
2025 Q1	$315K	Buy	40,910 +8,880	+28%	+$111K	0.1%	176
2024 Q4	$476K	Buy	+32,030	New	+$497K	0.15%	133

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Guidance Capital's NEO Position: Q1 2026 in Review

Guidance Capital sold out of NeoGenomics (NEO) in Q1 2026, closing a stake of 55,869 shares — an estimated $725K sold.

Guidance Capital first reported a position in NEO in Q4 2024 and held it in 5 quarters. The position peaked at $725K in Q4 2025. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

Guidance Capital reported no remaining NeoGenomics position as of Q1 2026 after selling out during the quarter.
Guidance Capital sold 55,869 NeoGenomics shares in Q1 2026, an estimated $725K.
Guidance Capital first reported a position in NeoGenomics in Q4 2024 and held it in 5 quarters.
Guidance Capital's NeoGenomics position peaked at $725K in Q4 2025.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Guidance Capital's 13F filing for Q1 2026, filed 8 May 2026.